Modality
Fusion Protein
MOA
GLP-1/GIP
Target
MALT1
Pathway
Proteasome
Bladder Ca
Development Pipeline
Preclinical
Apr 2024
→ Jan 2028
PreclinicalCurrent
NCT03273811
1,986 pts·Bladder Ca
2024-04→2028-01·Active
1,986 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-161.8y awayInterim· Bladder Ca
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
Preclinical
Active
Catalysts
Interim
2028-01-16 · 1.8y away
Bladder Ca
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03273811 | Preclinical | Bladder Ca | Active | 1986 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 |